These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 31621054

  • 1. The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.
    Muehler A, Kohlhof H, Groeppel M, Vitt D.
    Drugs R D; 2019 Dec; 19(4):351-366. PubMed ID: 31621054
    [Abstract] [Full Text] [Related]

  • 2. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
    Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF.
    J Crohns Colitis; 2013 Sep; 7(8):636-43. PubMed ID: 23078909
    [Abstract] [Full Text] [Related]

  • 3. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
    Muehler A, Peelen E, Kohlhof H, Gröppel M, Vitt D.
    Mult Scler Relat Disord; 2020 Aug; 43():102129. PubMed ID: 32428844
    [Abstract] [Full Text] [Related]

  • 4. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
    Muehler A, Kohlhof H, Groeppel M, Vitt D.
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):557-573. PubMed ID: 32361977
    [Abstract] [Full Text] [Related]

  • 5. A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis.
    Fox RJ, Wiendl H, Wolf C, De Stefano N, Sellner J, Gryb V, Rejdak K, Bozhinov PS, Tomakh N, Skrypchenko I, Muehler AR.
    Ann Clin Transl Neurol; 2022 Jul; 9(7):977-987. PubMed ID: 35698927
    [Abstract] [Full Text] [Related]

  • 6. Leflunomide in the treatment of rheumatoid arthritis.
    Li EK, Tam LS, Tomlinson B.
    Clin Ther; 2004 Apr; 26(4):447-59. PubMed ID: 15189743
    [Abstract] [Full Text] [Related]

  • 7. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
    Goldenberg MM.
    Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
    [Abstract] [Full Text] [Related]

  • 8. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I.
    Arch Intern Med; 1999 Nov 22; 159(21):2542-50. PubMed ID: 10573044
    [Abstract] [Full Text] [Related]

  • 9. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
    Wiese MD, Hopkins AM, King C, Wechalekar MD, Lee A, Spargo L, Metcalf R, McWilliams L, Hill C, Cleland LG, Proudman SM.
    Arthritis Care Res (Hoboken); 2021 Jul 22; 73(7):983-989. PubMed ID: 32339392
    [Abstract] [Full Text] [Related]

  • 10. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG, Halilovic J, Stan-Ugbene O.
    Clin Ther; 2010 Sep 22; 32(10):1681-703. PubMed ID: 21194591
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, Zhou Y, Mohamed MF, Meerwein S, Pangan AL.
    Lancet; 2018 Jun 23; 391(10139):2513-2524. PubMed ID: 29908670
    [Abstract] [Full Text] [Related]

  • 12. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW, TOPIC Study Group.
    Lancet Neurol; 2014 Oct 23; 13(10):977-86. PubMed ID: 25192851
    [Abstract] [Full Text] [Related]

  • 13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators.
    Lancet; 2009 Jul 18; 374(9685):210-21. PubMed ID: 19560810
    [Abstract] [Full Text] [Related]

  • 14. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
    Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson JA, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM.
    Ann Intern Med; 2002 Nov 05; 137(9):726-33. PubMed ID: 12416946
    [Abstract] [Full Text] [Related]

  • 15. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep 05; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 16. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
    Vanhoutte F, Mazur M, Voloshyn O, Stanislavchuk M, Van der Aa A, Namour F, Galien R, Meuleners L, van 't Klooster G.
    Arthritis Rheumatol; 2017 Oct 05; 69(10):1949-1959. PubMed ID: 28622463
    [Abstract] [Full Text] [Related]

  • 17. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
    Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M.
    Pharmacogenomics; 2009 Feb 05; 10(2):303-9. PubMed ID: 19207032
    [Abstract] [Full Text] [Related]

  • 18. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.
    Clin Ther; 2003 Jun 05; 25(6):1700-21. PubMed ID: 12860493
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
    Kaur H, Sarma P, Bhattacharyya A, Sharma S, Chhimpa N, Prajapat M, Prakash A, Kumar S, Singh A, Singh R, Avti P, Thota P, Medhi B.
    Eur J Pharmacol; 2021 Sep 05; 906():174233. PubMed ID: 34111397
    [Abstract] [Full Text] [Related]

  • 20. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S.
    Lancet; 2019 Jun 08; 393(10188):2303-2311. PubMed ID: 31130260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.